These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
428 related items for PubMed ID: 14657430
1. The effect of incentive-based formularies on prescription-drug utilization and spending. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. N Engl J Med; 2003 Dec 04; 349(23):2224-32. PubMed ID: 14657430 [Abstract] [Full Text] [Related]
3. Effect of tiered prescription copayments on the use of preferred brand medications. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Med Care; 2003 Mar 04; 41(3):398-406. PubMed ID: 12618643 [Abstract] [Full Text] [Related]
4. Incentive formularies and changes in prescription drug spending. Landon BE, Rosenthal MB, Normand SL, Spettell C, Lessler A, Underwood HR, Newhouse JP. Am J Manag Care; 2007 Jun 04; 13(6 Pt 2):360-9. PubMed ID: 17567237 [Abstract] [Full Text] [Related]
5. Controlling prescription drug expenditures: a report of success. Miller DP, Furberg CD, Small RH, Millman FM, Ambrosius WT, Harshbarger JS, Ohl CA. Am J Manag Care; 2007 Aug 04; 13(8):473-80. PubMed ID: 17685828 [Abstract] [Full Text] [Related]
8. Employer drug benefit plans and spending on prescription drugs. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. JAMA; 2002 Oct 09; 288(14):1733-9. PubMed ID: 12365957 [Abstract] [Full Text] [Related]
9. Impact of cost sharing on prescription drugs used by Medicare beneficiaries. Goedken AM, Urmie JM, Farris KB, Doucette WR. Res Social Adm Pharm; 2010 Jun 09; 6(2):100-9. PubMed ID: 20511109 [Abstract] [Full Text] [Related]
11. Are incentive-based formularies inversely associated with drug utilization in managed care? Gleason PP, Gunderson BW, Gericke KR. Ann Pharmacother; 2005 Feb 09; 39(2):339-45. PubMed ID: 15644478 [Abstract] [Full Text] [Related]
12. The effect of a three-tier formulary on antidepressant utilization and expenditures. Hodgkin D, Parks Thomas C, Simoni-Wastila L, Ritter GA, Lee S. J Ment Health Policy Econ; 2008 Jun 09; 11(2):67-77. PubMed ID: 18509214 [Abstract] [Full Text] [Related]
13. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Am J Manag Care; 2005 Oct 09; 11(10):621-8. PubMed ID: 16232003 [Abstract] [Full Text] [Related]
14. A bitter pill: formulary variability and the challenge to prescribing physicians. Shrank WH, Ettner SL, Glassman P, Asch SM. J Am Board Fam Pract; 2004 Oct 09; 17(6):401-7. PubMed ID: 15575031 [Abstract] [Full Text] [Related]
15. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans. Clark BE, Siracuse MV, Garis RI. Res Social Adm Pharm; 2009 Jun 09; 5(2):133-42. PubMed ID: 19524861 [Abstract] [Full Text] [Related]
16. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. N Engl J Med; 2002 Mar 14; 346(11):822-9. PubMed ID: 11893794 [Abstract] [Full Text] [Related]
17. Incentive-based formularies. Thomas CP. N Engl J Med; 2003 Dec 04; 349(23):2186-8. PubMed ID: 14657424 [No Abstract] [Full Text] [Related]
18. Effect of incentive-based formularies on drug utilization and spending. Sandy LG, Heady T. N Engl J Med; 2004 Mar 04; 350(10):1057. PubMed ID: 15002122 [No Abstract] [Full Text] [Related]